Innate Pharma S.A. ADS - IPHA STOCK NEWS

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has released its share and voting rights data as of December 31, 2024. The company reported 83,830,336 ordinary shares, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 84,585,576, which includes voting rights attached to AGAP 2016 (130 voting rights for AGAP 2016-1 and 111 for AGAP 2016-2). The total number of exercisable voting rights is 84,567,001, calculated excluding treasury shares. No voting rights are attached to AGAP 2017.

Innate Pharma (Nasdaq: IPHA) announced a new growth strategy based on three key pillars: driving innovation with their proprietary ANKET® NK-cell engager Platform, accelerating development of Antibody-Drug Conjugates (ADCs), and advancing late-stage assets through partnerships.

The company is developing IPH6501, an ANKET® therapy currently in Phase 1/2 study for CD20-expressing non-Hodgkin's Lymphoma, and IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 in Phase 1 trials for advanced solid tumors.

For late-stage assets, Innate is seeking partners for lacutamab in advanced T cell lymphomas, while monalizumab, partnered with AstraZeneca, is in Phase 3 PACIFIC-9 trial for non-small cell lung cancer with readouts expected by end of 2026.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco. CEO Jonathan Dickinson will present on Tuesday, January 14, 2025, from 11:15 - 11:55 am PST.

The company's executive team, including Dr Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Arvind Sood (EVP, President of US Operations), will participate in 1x1 meetings during the conference. A live video webcast of the presentation will be available on the company's website under the 'Events' tab in the Investors section.

Innate Pharma presented new data from the TELLOMAK Phase 2 study showing quality-of-life improvements in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab. The study included 163 patients: 56 with Sézary syndrome (SS) and 107 with mycosis fungoides (MF).

Key findings for SS patients showed reduction in itch intensity from Week 5, reaching mild levels by Week 13. Skin-related symptoms improved significantly, with Skindex-29 scores decreasing from 52.7 at baseline to 14.4 by Week 45.

For MF patients, itch intensity improved from Week 5, with deeper improvement from Week 37. Skindex-29 scores showed early reductions, decreasing from 56.3 to 38.8 by Week 29.

Translational analysis revealed lacutamab's effectiveness in depleting KIR3DL2-expressing circulating tumor cells and skin cells, supporting its potential as a treatment option for SS patients.

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have announced a partnership worth up to $7.9 million to support the development of IPH6501 in follicular lymphoma. The agreement includes a $3 million upfront investment from IFLI in Innate shares at €1.56 per share, representing 2.26% of Innate's share capital, with potential additional investments of up to $4.9 million tied to milestone achievements.

The collaboration will expand Innate's ongoing Phase 1/2 trial of IPH6501, an anti-CD20 ANKET®, to include patients with relapsed/refractory follicular lymphoma. The trial is currently investigating the safety, tolerability, and preliminary antineoplastic activity in patients with CD20-expressing Non-Hodgkin Lymphoma.

Innate Pharma (Nasdaq: IPHA) announced the selection of multiple abstracts for presentation at the ASH Annual Meeting 2024. The presentations will feature data on lacutamab from the TELLOMAK Phase 2 trial, including health-related quality of life and translational analysis in patients with Sézary Syndrome. Additionally, data will be presented on SAR443579, a Sanofi-partnered ANKET® asset, in combination with venetoclax and azacitidine for newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its financial calendar for 2025. The schedule includes four major financial disclosures: 2024 financial statements on March 27, first quarter 2025 revenue and cash position on May 13, half-year financial statements on September 17, and third quarter 2025 revenue and cash position on November 13. The company's Annual General Shareholders Meeting is scheduled for May 22, 2025. All financial reports will be released before market open CET.

Innate Pharma announced the publication in Science Immunology of preclinical data for IPH6501, a tetra-specific NK cell engager targeting CD20 for B-NHL treatment. The study demonstrates that IPH6501 enhances NK cell proliferation and cytotoxicity, showing effectiveness against various B-NHL cell lines, including those with low CD20 density. In vivo studies confirmed its efficacy and ability to induce NK cell migration to tumor sites. The data revealed superior killing efficacy compared to T cell engagers while showing reduced toxicities. IPH6501 is currently being evaluated in a Phase 1/2 clinical trial for B-cell non-Hodgkin lymphoma.

Innate Pharma reported its Q3 2024 business update with several key developments. Jonathan Dickinson was appointed as CEO and Chairman of the Executive Board. The company received encouraging FDA feedback on lacutamab's regulatory pathway and FDA clearance for IPH4502, a Nectin-4 ADC for solid tumors. The cash position stood at €96.4 million as of September 30, 2024, with runway until end of 2025. Revenue for the first nine months of 2024 was €10.2 million, compared to €36.5 million in the same period of 2023. Multiple clinical trials are progressing, including TELLOMAK Phase 2 for lacutamab and various ANKET® platform developments.